A high plasma homocysteine concentration is associated with premature vascular disease and thrombosis. The association between high homocysteine concentrations and thrombosis in patients with a normal coagulation profile is unknown. Sixty adults (37 men and 23 women, mean age 46 years) with documented thrombosis were compared with age-and sex-matched controls. Those with risk factors for thrombosis or abnormal coagulation profiles were excluded. Homocysteine concentrations were higher in cases than controls (21.8 ± 13.8 vs 11.0 ± 4.7 μmol/L, p < 0.001). A cut point for defining high homocysteine concentrations was determined at 13 μmol/L and conferred an increased odds ratio for thrombosis overall (7.8, 95% CI 3.0-20.2, p < 0.001) as well as in men (8.9, 95% CI 3.0-26.1; p < 0.001) and women (37.8, 95% CI 6.5-213.9; p < 0.01). A high plasma homocysteine is a risk factor for thrombosis in patients with a normal coagulation profile. This common abnormality should be sought in patients with otherwise unexplained thrombotic episodes. Key Words: Homocysteine—Thrombosis—Clotting.
Get full access to this article
View all access options for this article.
References
1.
Carson Naj, Neil DWMetabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child1962;37:505.
2.
Mudd SHLevy HL, Skovby F.Disorders of transulfurafion. In: Scriber C, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease, 6th ed. Vol 1. New York: McGraw-Hill, 1989:693.
3.
Mudd SH, Skovby F., Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet1985;37:1.
4.
Wilcken Del, Wilcken B.The pathogenesis of coronary artery disease: A possible role for methionine metabolism. J Clin Invest1976;57:1079.
5.
Boers Ghj, Smals Agh, Trijbels Fjm, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med1985;313:709.
6.
Brattström L. , Israelsson B., Norrving B., et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis1990;81:51.
7.
Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med1991; 324:1149.
8.
Genest JJ Jr, McNamara JR, Salem DN, et al. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol1990,16:1114.
9.
Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation1989 ;79:1180.
10.
Taylor LM Jr, DeFrang RD, Harris J. Jr, et al. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg1991:13:128.
11.
Brattström L., Lindgren A., Israelsson B., et al. Hyperhomocysteinaemia in stroke: Prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest1992;22:214.
12.
Stampfer MJ , Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc1992:268:877.
13.
Dudman Npb, Wilcken Del, Wang J., et al. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb1993;13:1253.
14.
Graham IMHomocysteinaemia and vascular disease. In: Vuylsteek K.Hallen M, eds. Commission of the European Community. Luxembourg: los Press, 1994:332.
15.
Wu LL, Wu J., Hunt SC, et al. Plasma homocysteine as a risk factor for early familial coronary artery disease. Clin Chem1994;40:552.
16.
Pancharuniti N., Lewis CA, Sauberlich HE, et al. Plasma homo-cyst(e)ine, folate, and vitamin B 12 concentrations and risk for early-onset coronary artery disease . Am J Clin Nutr1994:59:940.
17.
Robinson K. , Mayer E., Miller D., et al. Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease. Circulation1995;92:2825.
18.
Jacobsen DW , Gatautis VJ, Green R., et al. Rapid HPLC determi. nation of total homocysteine and other thiols in serum and plasma: Sex differences and correlation with cobalamin and folate levels in healthy subjects. Clin Chem1994;40:873.
19.
Brattstrom L., Tengborn L., Lagerstedt C., et al. Plasma homocysteine in venous thromboembolism . Haemostasis1991;21:51.
20.
Bienvenu T. , Ankri A., Chadefaux B., et al. Elevated total plasma homocysteine, a risk factor for thrombosis: Relation to coagulation and fibrinolytic parameters . Thromb Res1993;70:123.
21.
Falcon CR, Cattaneo M., Panzeri D., et al. High prevalence of hyperhomocyst(e)inehia in patients with juvenile thrombosis. Arterioscl Thromb1994;14:1080.
22.
den Heijer M., Blom HJ, Gerrits Wwbj, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet1995;345:882.
23.
Amundsen T. , Ueland PM, Waage A.Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol1995;15:1321.
24.
Ueland PM, Refsum H., Brattström L.Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York: Marcel Dekker, Inc., 1992:183.
25.
Rodgers GM, Conn MTHomocysteine, atherogenic stimulus, reduces protein-C activation by arterial and venous endothelial cells. Blood1990;75:895.
26.
Bertina RM, Koeleman Bpc, Koster T., et al. Mutation in blood, coagulation factor V associated with resistance to activated protein C. Nature1994;369:64.
27.
Dahlback B.Inherited thrombophilia: Resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood1995 ;85:607.
28.
Harker LA, Slichter SJ, Scott CR, et al. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med1974;291:537.
29.
Graeber JE, Slott JH, Ulane RE, et al. Effect of homocysteine and homocystine on platelets and vascular arachidonic acid metabolism. Paediatr Res1982; 16.490.
30.
Di Minno G, Davi G., Margaglione M., et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest1993;92:1400.
31.
Kang S-S., Wong Pwk, Norusis M.Homocysteinemia due to folate deficiency. Metabolism1987;36:458.
32.
Stabler SP, Marcell PD, Podell ER, et al. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest1988;81:466,
33.
Brattström LE, Israelsson B., Lindgarde F., et al. Higher total plasma homocysteine in vitamin B 12 deficiency than in heterozygosity for homocystinuria due to cystathionine β-synthase deficiency. Metabolism1988;37:175.
34.
Selhub J., Jacques PF, Wilson Pwf, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc1993 ;270:2693.
35.
Brattström LE, Israelsson B., Jeppsson J-O., et al. Folic acid—an innocuous means to reduce plasma homoeysteine. Scand J Clin Lab Invest1988;48:215.
36.
Franken DG, Boers Ghj, Blom HJ, et al. Treatment of mild hyperhomocysteinemia in vascular disease patients . Arterioscler Thromb, 1994; 14:465.
37.
Ryan M., Robinson K., Clarke R., et al. Vitamin B6 and folate reduce homocysteine concentrations in coronary artery disease. [Abstract] Ir J Med Sci1993; 162:197.
38.
Ubbink JB, Vermaak Wjh, van der Merwe A., et al. Vitamin B-12. vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr1993;57-:47.
39.
Kang S-S., Passen EL, Ruggie N., et al. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation1993;8:1463.
40.
Kang S-S., Wong Pwk, Susmano A., et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet1991;48:536.
41.
Fenton WA, Rosenberg LEInherited disorders of cobalamin transport and metabolism. In: Scriber C, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease, 6th ed. Vol 1. New York: McGraw-Hill , 1989:693.
42.
Goyette P., Sumner JS, Milos R., et al. Human methyleneterahydrofolate reductase: Isolation of cDNA, mapping and mutation identification (published erratum appears in Nat Genet1994;7: 551). Nat Genet1994;7:195.
43.
Frosst P., Blom HJ, Milos R., et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet1995; 10: 111.
